A recent scientific review has highlighted ivermectin’s potential anti-cancer properties. “Its broad range of anticancer mechanisms… support its candidacy for repurposing,” the paper notes.
Ivermectin, widely known for its use in parasitic treatments, is now gaining attention for its potential in cancer therapy. A new peer-reviewed study titled “A Review of Ivermectin Use in Cancer Patients: Is it Time to Repurpose the Ivermectin in Cancer Treatment?” was published in Acta Poloniae Pharmaceutica – Drug Research.
According to the McCullough Foundation, the review—described as the most comprehensive to date—found ivermectin to be safe even in patients undergoing chemotherapy. The authors noted, “Its broad range of anticancer mechanisms demonstrated in preclinical models, combined with anecdotal reports of cancer-related improvements, support its candidacy for repurposing as an oncologic therapy.”
Experts like Dr. William Makis have called for large-scale clinical trials to assess the drug’s full potential. The report also noted promising results when ivermectin is combined with mebendazole, another antiparasitic drug.
Medical advocates argue that censorship has limited access to these therapies and are urging further research into their use for cancer treatment.